S/GSK1349572: Phase IIb data

In the ongoing, open-label Phase IIb VIKING trial in 27 patients with HIV resistant to Isentress raltegravir and screening plasma HIV-1 RNA levels >=1,000 copies/mL, once-daily 50 mg S/GSK1349572 red...